Total dose radiation hardened PDSOI CMOS 3-line to 8-line decoder

被引：0
|
作者：
Liu, Mengxin [1 ]
Han, Zhengsheng [1 ]
Li, Duoli [1 ]
Liu, Gang [1 ]
Zhao, Chaorong [1 ]
Zhao, Fazhan [1 ]
机构：
[1] Institute of Microelectronics, Chinese Academy of Sciences, Beijing 100029, China
来源：
Pan Tao Ti Hsueh Pao/Chinese Journal of Semiconductors | 2008年 / 29卷 / 06期
关键词：
12;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1036 / 1039
相关论文
共 24 条
  • [21] THE V-ABL, C-FMS, OR V-MYC ONCOGENE INDUCES GAMMA-RADIATION RESISTANCE OF HEMATOPOIETIC PROGENITOR-CELL LINE 32D CL 3 AT CLINICAL LOW-DOSE RATE
    FITZGERALD, TJ
    SANTUCCI, MA
    DAS, I
    KASE, K
    PIERCE, JH
    GREENBERGER, JS
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (05): : 1203 - 1210
  • [22] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
    Clamp, Andrew R.
    James, Elizabeth C.
    McNeish, Iain A.
    Dean, Andrew
    Kim, Jae-Won
    O'Donnell, Dearbhaile M.
    Gallardo-Rincon, Dolores
    Blagden, Sarah
    Brenton, James
    Perren, Tim J.
    Sundar, Sudha
    Lord, Rosemary
    Dark, Graham
    Hall, Marcia
    Banerjee, Susana
    Glasspool, Rosalind M.
    Hanna, C. Louise
    Williams, Sarah
    Scatchard, Kate M.
    Nam, Helena
    Essapen, Sharadah
    Parkinson, Christine
    McAvan, Lucy
    Swart, Ann Marie
    Popoola, Babasola
    Schiavone, Francesca
    Badrock, Jonathan
    Fananapazir, Fuad
    Cook, Adrian D.
    Parmar, Mahesh
    Kaplan, Richard
    Ledermann, Jonathan A.
    LANCET ONCOLOGY, 2022, 23 (07): : 919 - 930
  • [23] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
    Clamp, Andrew R.
    James, Elizabeth C.
    McNeish, Iain A.
    Dean, Andrew
    Kim, Jae-Weon
    O'Donnell, Dearbhaile M.
    Hook, Jane
    Coyle, Christopher
    Blagden, Sarah
    Brenton, James D.
    Naik, Raj
    Perren, Tim
    Sundar, Sudha
    Cook, Adrian D.
    Gopalakrishnan, Gosala S.
    Gabra, Hani
    Lord, Rosemary
    Dark, Graham
    Earl, Helena M.
    Hall, Marcia
    Banerjee, Susana
    Glasspool, Rosalind M.
    Jones, Rachel
    Williams, Sarah
    Swart, Ann Marie
    Stenning, Sally
    Parmar, Mahesh
    Kaplan, Richard
    Ledermann, Jonathan A.
    LANCET, 2019, 394 (10214): : 2084 - 2095
  • [24] DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC)
    Peters, Solange
    Champiat, Stephane
    Yoshida, Tatsuya
    Dorleacq, Nicolas
    Ma, Yiyuan
    Geng, Lijiang
    Leal, Ticiana
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
123